Q-linea AB (3F80) AI Stock Analysis

Q-linea AB

(Frankfurt:3F80)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthRevenue growth indicates that Q-linea is achieving some commercial traction in infectious-disease diagnostics, despite its small base. If this expansion continues, greater instrument and consumable adoption could improve operating leverage and provide a foundation for future profitability.

Negative Factors

Persistent UnprofitabilityDeeply negative gross profit shows that Q-linea is not yet covering the direct economics of its business, while operating and net losses indicate additional costs remain unsupported by revenue. This weak profitability limits internally funded growth and makes sustainable earnings dependent on substantial improvement in economics.

Q-linea AB (3F80) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 25.76M
Dividend Yield: ―
Average Volume (3M): 8
Price to Earnings (P/E): -1.1
Beta (1Y): 82.04
Revenue Growth: 35.65%
EPS Growth: 90.34%
Country: Germany
Employees: 70
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

Q-linea AB Business Overview & Revenue Model

Company Description

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicr...

Q-linea AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:3F80 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CEVI	83Outperform	SEK 4.67B	33.84	15.23%	1.41%	1.95%	-8.91%
SE:SEZI	57Neutral	SEK 532.17M	-5.46	-35.44%	―	18.56%	28.11%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ALZ	44Neutral	SEK 112.04M	-1.68	-17.52%	―	-100.00%	20.94%
SE:ACARIX	40Underperform	SEK 223.04M	-5.29	-100.09%	―	65.82%	41.28%
SE:BOUL	38Underperform	SEK 40.19M	-2.31	-58.52%	―	-16.09%	78.68%

* Healthcare Sector Average

Performance Comparison

DE:3F80 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:3F80	Q-linea AB	1.31	-0.96	-42.07%
SE:BOUL	Boule Diagnostics AB	1.03	-5.45	-84.03%
SE:CEVI	CellaVision AB	195.60	17.76	9.98%
SE:SEZI	Senzime AB	3.38	-2.45	-41.94%
SE:ALZ	Alzinova AB	0.35	-1.07	-75.14%
SE:ACARIX	Acarix AB	0.18	-0.10	-35.61%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Q-linea AB AI Stock Analysis